DARE - Daré Bioscience hits seven-month high after regaining listing compliance

• The women’s health company Daré Bioscience ( NASDAQ: DARE ) added ~13% on Wednesday to reach the highest level since June 2022 after announcing that its shares have regained Nasdaq compliance for continued listing.
• According to a Nasdaq communication on Jan. 24, Daré ( DARE ) has regained compliance with the Nasdaq’s minimum bid price rule as its closing bid price has remained at $1 or above for at least ten consecutive days, the company said.
• Daré ( DARE ) shares have added ~50% over the past six months, but the stock trades ~18% below the year-ago levels, as indicated in this graph.
• Despite recent FDA approval for the company’s Xaciato vaginal gel for bacterial vaginosis, Seeking Alpha contributor Busted IPO Forum reaffirmed Hold rating on Daré ( DARE ) early this month, citing concerns over the product launch.

For further details see: